CDKL5 Deficiency Disorder Market

CDKL5 deficiency disorder (CDD) is a rare developmental epileptic encephalopathy (DEE), X-linked genetic condition which results in early-onset, difficult to control seizures and severe neuro-developmental impairment. CDKL5 stands for cyclin-dependent kinase-like 5 and mutations in this gene were first identified as disease-causing in 2004. CDD was previously not considered as a separate indication; rather, it was assumed to be an atypical form of Rett Syndrome. The CDKL5 gene provides instructions for making proteins that are essential for normal brain and neuron development. The condition was previously known as serine/threonine-protein kinase 9 (STK9), and it has been classified as DEE because the genetic change causes epileptic activity as well as severe impairment of the development. The CDKL5 gene is located on the X chromosome. The X chromosome is one of the sex chromosomes; females have two Xs, and males have one X and one Y chromosome. Although many identified patients are males, because of the location of the gene, this disorder mainly affects females. Affected males may have more severe symptoms than females.

CDKL5 Deficiency Disorder Market contains market size and forecasts of CDKL5 Deficiency Disorder (CDD) in Global, including the following market information:

• Global CDKL5 Deficiency Disorder (CDD) Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global CDKL5 Deficiency Disorder (CDD) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Traditional Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of CDKL5 Deficiency Disorder (CDD) include Marinus Pharmaceuticals, Ovid Therapeutics/Takeda, Zogenix and PTC Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the CDKL5 Deficiency Disorder (CDD) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global CDKL5 Deficiency Disorder (CDD) Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global CDKL5 Deficiency Disorder (CDD) Market Segment Percentages, by Type, 2021 (%)

• Traditional Drugs
• Emerging Drugs

Global CDKL5 Deficiency Disorder (CDD) Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global CDKL5 Deficiency Disorder (CDD) Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinic
• Others

Global CDKL5 Deficiency Disorder (CDD) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global CDKL5 Deficiency Disorder (CDD) Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies CDKL5 Deficiency Disorder (CDD) revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies CDKL5 Deficiency Disorder (CDD) revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Marinus Pharmaceuticals
• Ovid Therapeutics/Takeda
• Zogenix
• PTC Therapeutics